China H1N1 Flu Vaccine Maker Says Passed Phase I Trial
This article was originally published in PharmAsia News
Executive Summary
Sinovac Biotech of China said its H1N1 flu vaccine has passed a Phase I trial without severe adverse reactions for as long as three days after inoculation. The company plans to publish a preliminary report on its vaccine by mid-August. Sinovac, also known as Beijing Kexing Bioproducts, expects to complete trials in mid-September, testing it on a range of ages from 3 years old to 60 years old. (Click here for more